Boehringer Ingelheim Animal Health announced the recipients of the 2022 Advancement in Equine Research Awards during the 68th annual American Association of Equine Practitioners Convention in San Antonio, TX, November 18-22.
Equine infectious respiratory disease and equine asthma syndrome research projects receive $75,000 in funding from Boehringer Ingelheim Animal Health.
© 2016 by Alexander Raths New window.
The recipients were chosen based on their research proposals centered on equine infectious respiratory disease and equine asthma syndrome.
Recipients include the following:
- Renaud Leguillette, DVM, MSc., PhD, DACVIM, ACVSMR and Macarena Sanz, DVM, PhD, DACVIM, University of Calgary College of Veterinary Medicine, Calgary, AB, Canada
- Shadira Gordon, DVM, MPVM and Nicola Pusterla, DVM, PhD, DACVIM, DAVDC, University of California, Davis, Davis, CA
- Noah D. Cohan, VMD, MPH, PhD, Texas AgriLife Research – College of Veterinary Medicine, College Station, Texas
- Shannon Massie, MS and Renaud Leguillette, DVM, MSc., PhD, DACVIM, ACVSMR, University of Calgary College of Veterinary Medicine, Calgary, AB, Canada
- Shadira Gordon, DVM, MPVM, Nicola Pusterla, DVM, PhD, DACVIM, DAVDC and Beatriz Martinez Lopez, DVM, MPVM, PhD, University of California, Davis, Davis, CA
In support of their research, each recipient will receive $15,000. With the inclusion of this year’s recipients, Boehringer Ingelheim has given more than $700,000 towards the advancement of equine research since 2011.
“At Boehringer Ingelheim, we acknowledge that the health and well-being of animals is pivotal to the success and development of human life. Our dedication and passion for the advancement of equine research makes Boehringer Ingelheim a global leader in its field,” said Steve Grubbs, DVM, PhD, DACVIM, equine technical manager for BI.
“Previous award recipients have made novel research advancements in equine infectious and non-infectious respiratory diseases, and we anticipate that this year’s grantees will follow suit.”
Those eligible to submit proposals were veterinarians, diagnosticians, and public and private researchers in the United States, Canada and Mexico.
For more information about the Advancement in Equine Research Awards, click here.
About Boehringer Ingelheim Animal Health USA
Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals. For veterinarians, pet owners, producers, and governments in more than 150 countries, we offer a large and innovative portfolio of products and services to improve the health and well-being of companion animals and livestock.
As a global leader in the animal health industry and as part of the family-owned Boehringer Ingelheim, we take a long-term perspective. The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. By using the synergies between our Animal Health and Human Pharma businesses and by delivering value through innovation, we enhance the health and well-being of both.
Boehringer Ingelheim Animal Health has deep roots in the U.S. From a start in St. Joseph, Missouri, more than 100 years ago, it has grown to encompass seven sites. Boehringer Ingelheim Animal Health’s portfolio contains widely used and well-respected vaccines, parasite-control products and therapeutics for pets, horses and livestock including NexGard®, Heartgard®, Pyramid® + Presponse®, VAXXITEK®, Ingelvac CircoFLEX® and Prascend®.
Learn more about Boehringer Ingelheim Animal Health USA at bi-animalhealth.com
Press release by Boehringer Ingelheim